Bernardo Cortese

Summary

Publications

  1. Cortese B. Letter regarding the article "Transradial access compared with femoral puncture closure devices in percutaneous coronary procedures": an underestimated revolution. Int J Cardiol. 2010;145:383 pubmed publisher
    ..We comment on the possibility of using a stronger antithrombotic treatment in case of high risk percutaneous interventions. Is scientific evidence regarding the transradial approach enough to warrant its widespread use? ..
  2. Cortese B, Bertoletti A, De Matteis S, Danzi G, Kastrati A. Drug-eluting stents perform better than bare metal stents in small coronary vessels: a meta-analysis of randomised and observational clinical studies with mid-term follow up. Int J Cardiol. 2012;161:73-82 pubmed publisher
    ..DES are superior to BMS in terms of their efficacy in managing small coronary arteries (diameter<3mm), and at least equivalent in terms of safety. The use of DES should be considered the treatment of choice in this setting. ..
  3. Cortese B, Silva Orrego P, Agostoni P, Buccheri D, Piraino D, Andolina G, et al. Effect of Drug-Coated Balloons in Native Coronary Artery Disease Left With a Dissection. JACC Cardiovasc Interv. 2015;8:2003-2009 pubmed publisher
    ....
  4. Cortese B, Piraino D, Buccheri D, Alfonso F. Treatment of bifurcation lesions with drug-coated balloons: A review of currently available scientific data. Int J Cardiol. 2016;220:589-94 pubmed publisher
    ..We review here the currently available scientific data and future perspectives on drug-coated balloon use for bifurcation lesions. ..
  5. Cortese B, Di Palma G, Latini R. Magic Touch: preliminary clinical evidence with a novel Sirolimus drug coated balloon. Minerva Cardioangiol. 2018;: pubmed publisher
    ..This device shares a new-generation delivery system and is able to release in a few seconds an effective dosage of sirolimus. ..
  6. Cortese B, Picchi A, Micheli A, Limbruno U. Intracoronary bivalirudin for no reflow reversal: a second chance to treat this disorder?. J Thromb Thrombolysis. 2009;28:74-6 pubmed publisher
    ..We showed how bivalirudin, a drug whose use is increasing in the catheterization laboratories, could be safely used via the intracoronary route to treat no reflow phenomenon due to distal microembolization in a complex patient. ..
  7. Cortese B, Micheli A, Picchi A, Bandinelli L, Brizi M, Severi S, et al. Safety and efficacy of a prolonged bivalirudin infusion after urgent and complex percutaneous coronary interventions: a descriptive study. Coron Artery Dis. 2009;20:348-53 pubmed publisher
    ....
  8. Cortese B, Piraino D, Latini R, Zavalloni D, Ielasi A, Agostoni P, et al. Final shape of biovascular scaffolds and clinical outcome. Results from a multicenter all-comers study with intravascular imaging. Int J Cardiol. 2017;228:209-213 pubmed publisher
    ..In an all-comer population with complex coronary lesions treated with BVS, a final oval shape after postdilation was not rare and not associated with immediate and medium term adverse events. ..
  9. Cortese B, Di Palma G, Latini R, Elwany M, Orrego P, Seregni R. Immediate and short-term performance of a novel sirolimus-coated balloon during complex percutaneous coronary interventions. The FAtebenefratelli SIrolimus COated-balloon (FASICO) registry. Cardiovasc Revasc Med. 2017;18:487-491 pubmed publisher
    ..SCB shows high immediate technical performance and adequate short-term efficacy and safety. The ongoing EASTBOURNE registry will shed light on mid-and long-term performance of this device in an adequately powered population. ..
  10. Elwany M, Latini R, Di Palma G, Orrego P, Cortese B. First experience of drug-coated balloons for treatment of bioresorbable vascular scaffold restenosis. Cardiovasc Revasc Med. 2017;18:482-486 pubmed publisher
    ....

Detail Information

Publications13

  1. Cortese B. Letter regarding the article "Transradial access compared with femoral puncture closure devices in percutaneous coronary procedures": an underestimated revolution. Int J Cardiol. 2010;145:383 pubmed publisher
    ..We comment on the possibility of using a stronger antithrombotic treatment in case of high risk percutaneous interventions. Is scientific evidence regarding the transradial approach enough to warrant its widespread use? ..
  2. Cortese B, Bertoletti A, De Matteis S, Danzi G, Kastrati A. Drug-eluting stents perform better than bare metal stents in small coronary vessels: a meta-analysis of randomised and observational clinical studies with mid-term follow up. Int J Cardiol. 2012;161:73-82 pubmed publisher
    ..DES are superior to BMS in terms of their efficacy in managing small coronary arteries (diameter<3mm), and at least equivalent in terms of safety. The use of DES should be considered the treatment of choice in this setting. ..
  3. Cortese B, Silva Orrego P, Agostoni P, Buccheri D, Piraino D, Andolina G, et al. Effect of Drug-Coated Balloons in Native Coronary Artery Disease Left With a Dissection. JACC Cardiovasc Interv. 2015;8:2003-2009 pubmed publisher
    ....
  4. Cortese B, Piraino D, Buccheri D, Alfonso F. Treatment of bifurcation lesions with drug-coated balloons: A review of currently available scientific data. Int J Cardiol. 2016;220:589-94 pubmed publisher
    ..We review here the currently available scientific data and future perspectives on drug-coated balloon use for bifurcation lesions. ..
  5. Cortese B, Di Palma G, Latini R. Magic Touch: preliminary clinical evidence with a novel Sirolimus drug coated balloon. Minerva Cardioangiol. 2018;: pubmed publisher
    ..This device shares a new-generation delivery system and is able to release in a few seconds an effective dosage of sirolimus. ..
  6. Cortese B, Picchi A, Micheli A, Limbruno U. Intracoronary bivalirudin for no reflow reversal: a second chance to treat this disorder?. J Thromb Thrombolysis. 2009;28:74-6 pubmed publisher
    ..We showed how bivalirudin, a drug whose use is increasing in the catheterization laboratories, could be safely used via the intracoronary route to treat no reflow phenomenon due to distal microembolization in a complex patient. ..
  7. Cortese B, Micheli A, Picchi A, Bandinelli L, Brizi M, Severi S, et al. Safety and efficacy of a prolonged bivalirudin infusion after urgent and complex percutaneous coronary interventions: a descriptive study. Coron Artery Dis. 2009;20:348-53 pubmed publisher
    ....
  8. Cortese B, Piraino D, Latini R, Zavalloni D, Ielasi A, Agostoni P, et al. Final shape of biovascular scaffolds and clinical outcome. Results from a multicenter all-comers study with intravascular imaging. Int J Cardiol. 2017;228:209-213 pubmed publisher
    ..In an all-comer population with complex coronary lesions treated with BVS, a final oval shape after postdilation was not rare and not associated with immediate and medium term adverse events. ..
  9. Cortese B, Di Palma G, Latini R, Elwany M, Orrego P, Seregni R. Immediate and short-term performance of a novel sirolimus-coated balloon during complex percutaneous coronary interventions. The FAtebenefratelli SIrolimus COated-balloon (FASICO) registry. Cardiovasc Revasc Med. 2017;18:487-491 pubmed publisher
    ..SCB shows high immediate technical performance and adequate short-term efficacy and safety. The ongoing EASTBOURNE registry will shed light on mid-and long-term performance of this device in an adequately powered population. ..
  10. Elwany M, Latini R, Di Palma G, Orrego P, Cortese B. First experience of drug-coated balloons for treatment of bioresorbable vascular scaffold restenosis. Cardiovasc Revasc Med. 2017;18:482-486 pubmed publisher
    ....
  11. Cortese B, Ielasi A, Moscarella E, Loi B, Tarantini G, Pisano F, et al. Thirty-Day Outcomes After Unrestricted Implantation of Bioresorbable Vascular Scaffold (from the Prospective RAI Registry). Am J Cardiol. 2017;119:1924-1930 pubmed publisher
    ..In conclusion, our data of consecutive patients suggest that current use of BVS in a wide spectrum of coronary narrowings and clinical settings is associated with good outcome at 30 days. ..
  12. Di Palma G, Cortese B. Novel paclitaxel-coated scoring ballon for de novo complex coronary lesions-first report. Cardiovasc Revasc Med. 2017;: pubmed publisher
    ..We here describe our first experience treating two de novo coronary lesions with angiographic follow up. ..
  13. Di Palma G, Cortese B. Left-main restenosis in the DES era-a call for action. Cardiovasc Revasc Med. 2017;: pubmed publisher
    ..The optimal management of a ULM restenosis is still debated. Here we aim at presenting a review of the available data in literature and show our choice for treating it...